Fermenta Biotech Ltd · BSE:FERMENTA
Fermenta Biotech — Q1 FY27 Earnings Presentation
18 slides from Fermenta Biotech's earnings presentation, Aug 11, 2026
Slide 1: Intimation of Earnings Presentation to stock exchanges
August 11, 2026 BSE Limited National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers, Exchange Plaza, Plot No. C/1, Dalal Street, Fort, G Block, Bandra - Kurla Complex, Mumbai – 400 001 Bandra (East), Mumbai 400 051 Scrip Code: 506414 Trading Symbol: FERMENTA Dear Sir, Sub.: Intimation of
Slide 2: Fermenta Biotech Ltd Q1FY27 presentation
Fermenta Biotech Ltd Q1FY27 presentation 11 August 2026
Slide 3: Disclaimer
Disclaimer By viewing this presentation, the recipient agrees that neither Fermenta Biotech Limited (“FBL”) nor any of its affiliates, directors, officers, employees, or representatives shall be liable for any loss, damage, or liability arising directly or indirectly from the use of or reliance on t
Slide 4: Global demand for science-backed nutritional ingredients
As preventive healthcare awareness rises, global demand is accelerating for science-backed, top-quality nutritional ingredients. Fermenta pairs process and molecular expertise with science-validated capability to deliver best-in-class ingredients, trusted by leading brands across the pharmaceutical,
Slide 5: Q1FY27 Highlights
Q1FY27 Highlights Financials (consolidated) with and without Real Performance Estate Q1FY27 Q1FY27 ex-real Revenue near flat sequentially at INR 126.2 crore, flat estate QoQ, with human nutrition revenue up 24% QoQ to INR INR 124.3 crore 76.5 crore and segment volumes up 18% QoQ across INR 126.2 cro
Slide 6: Lines of Business
Lines of Business Nutrition Primary revenue source focused on nutritional ingredients for health and wellness industries Vitamin D3 - Human Vitamin D3 - Animal Others Premium supplements, food Specialized formulations for Customized Food Premixes, fortification, and pharmaceuticals livestock and pou
Slide 7: Revenue Mix (Consolidated)
Revenue Mix (Consolidated) Geographical Revenue Mix Q1FY27 Q4FY26 QoQ Q1FY26 YoY (consolidated) excluding real estate value (INR crore) (INR crore) change (%) (INR crore) change (%) unlocking Nutrition Business Vitamin D3 – Human 19% +1% 76.5 61.7 +24% 84.7 -10% 20% Nutrition Vitamin D3 – Animal 12.
Slide 8: Income Statement—Key Numbers (Consolidated)
Income Statement—Key Numbers (Consolidated) Amount in INR crore Q1FY27 Q1FY26 % Change INCOME Revenue from operations 121.8 136.3 The YoY comparison is against a strong Other income 4.4 8.8 April–June 2025 base: human nutrition Total Income 126.2 145.0 -13% volumes rose 18% QoQ, India reached 47% of
Slide 9: Cost Breakdown (Without Real Estate)
Cost Breakdown (Without Real Estate) Cost Structure Against the FY26 Base Raw material costs at 35% of revenue in Q1FY27, (% of Revenue) against 37% in FY26 (38% in FY25), which reflected an improved sourcing mix. Cost Component Q1FY27 FY26 FY25 Employee costs at 19% of revenue, against 16% in Raw M
Slide 10: The Opportunity
The Opportunity Unlocking growth: Fermenta’s unique position to meet evolving health and nutrition demands worldwide India Global Innovation Drivers ✓ Preventive health ✓ Nutritional supplements ✓ Plant-source actives awareness ✓ Ageing drives vitamin D ✓ Biocatalysis & green chemistry ✓ Growing mid
Slide 11: Strategy Map
Strategy Map Our Mission To harness our expertise in Innovation Chemistry and complex manufacturing at scale, delivering science-validated, leading-class solutions across nutrition, health and green chemistry, while creating lasting value for customers, society and investors Financial Financial Perf
Slide 12: Manufacturing and R&D
Manufacturing and R&D Enzymes and APIs including Vitamin D3 Customized premix plant Kullu Multiple global regulatory certifications Dedicated Vitamin D3 with Himachal Pradesh backward integration for cholesterol Collaboration with toll manufacturer for Vitamin Multiple global regulatory Dahej D3 500
Slide 13: Strategic Partnership Ecosystem
Strategic Partnership Ecosystem The Collaboration Strategic Value Global healthcare company Vitamin D awareness campaigns Extends our reach to healthcare specializing in diagnostics, Print and audiovisual educational materials professionals and patients medical devices, and nutrition Premier food te
Slide 14: FBL Certifications
FBL Certifications Comprehensive certifications demonstrate our commitment to meet diverse customer needs and global standards of quality, safety, sustainability, and ethical production. Adherence to stringent guidelines for GMP approval for dietary supplements European pharmaceutical markets Confir
Slide 15: R&D Focus Areas & Achievements
R&D Focus Areas & Achievements Focus Key Achievements Future Directions Calcifediol commercialization API Product pipelines Commercialized 11 products including Cholesterol, Lanolin derivatives VITADEE Green® Process improvement Enhanced Phenyramidol HCl process VITADEE SD (Spray Dried) Yield enhanc
Slide 16: Strategic Portfolio for Future Growth
Strategic Portfolio for Future Growth f Spray-Dried Vitamin D3 VITADEE Green® Calcifediol Customized Premixes ✓ 100,000 IU/g pharmaceutical-grade ✓ Plant-based Vitamin D3 with ✓ Next-generation Vitamin D ✓ Equipped with advanced instrumentation technology with CEP certification clean-label for vegan
Slide 17: Fermenta's Core Proposition
Fermenta’s Core Proposition Society Advance global health and preventive care through science-validated ingredients and actives Support life and productivity across human and animal populations Address environmental challenges through green chemistry and sustainable processes Best-in-class, science-
Slide 18: Thank you
Thank you Sumesh Gandhi - CFO sumesh.gandhi@fermentabiotech.com Fermenta Biotech Ltd